HomeMLTX • NASDAQ
MoonLake Immunotherapeutics
add
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 71.43M | 65.69% |
Net income | -69.73M | -97.03% |
Net profit margin | — | — |
Earnings per share | -1.10 | -96.43% |
EBITDA | -70.69M | -65.31% |
Effective tax rate | -0.16% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 380.48M | -22.97% |
Total assets | 414.34M | -20.05% |
Total liabilities | 123.14M | 442.21% |
Total equity | 291.19M | — |
Shares outstanding | 63.70M | — |
Price to book | 2.95 | — |
Return on assets | -40.85% | — |
Return on capital | -44.61% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -69.73M | -97.03% |
Cash from operations | -44.54M | -76.23% |
Cash from investing | 88.40M | 51.68% |
Cash from financing | 480.00K | 162.30% |
Net change in cash | 44.06M | 34.05% |
Free cash flow | -21.47M | -15.96% |
Previous close
$13.40
Day range
$13.18 - $13.60
Year range
$5.95 - $62.75
Market cap
949.69M USD
Avg Volume
3.40M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Founded
2020
Headquarters
Website
Employees
100
